Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial.
OBJECTIVE
To evaluate the effects of terazosin and tolterodine on ureteral stent discomfort.


METHODS
Of 163 patients assessed for eligibility, 104 patients were randomly assigned to receive placebo, 2 mg of terazosin twice daily, 2 mg of tolterodine daily, or both terazosin plus tolterodine during the stenting period. Prior to stenting and at stent removal, the International Prostate Symptom Score (IPSS), the IPSS quality of life (QoL) subscore and the Visual Analog Scale for Pain were determined. The patients also reported their analgesic use during the stenting period.


RESULTS
Ninety-four patients completed the study. We noted significant decreases in the total IPSS scores (p = 0.002), irritative subscore (p = 0.039), QoL (p = 0.001), flank pain (p = 0.013), voiding pain (p = 0.01) and amount of analgesics used (p = 0.02) in the groups. However, neither the obstructive subscore nor the suprapubic pain improved significantly (p = 0.251 and p = 0.522, respectively). The patients receiving terazosin plus tolterodine experienced significant reductions in the total IPSS, irritative symptoms, QoL, flank pain, voiding pain and decreased analgesics use compared with those patients receiving placebo. However, compared with placebo, terazosin monotherapy did not affect pain levels, and tolterodine monotherapy did not improve QoL, flank pain or analgesics use.


CONCLUSIONS
Terazosin plus tolterodine improves ureteral stent-related complications, including irritative symptoms, the amount of analgesics used, QoL, flank pain and voiding pain but does not decrease obstructive symptoms or suprapubic pain. This trial was registered at www.clinicaltrials.gov as NCT01530243.
Department of Urology, Urmia University of Medical Sciences, Urmia, Iran.
Ali
A
Tehranchi
Yousef
Y
Rezaei
Hamidreza
H
Khalkhali
Mahdi
M
Rezaei
D000293:Adolescent; D000328:Adult; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D003408:Cresols / Q000627:therapeutic use*; D020878:Device Removal / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D021501:Flank Pain / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010665:Phenylpropanolamine / Q000627:therapeutic use*; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D011788:Quality of Life; D015607:Stents / Q000009:adverse effects*; D011795:Surveys and Questionnaires; D013997:Time Factors; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D014513:Ureter / Q000187:drug effects*; D064804:Urological Agents / Q000627:therapeutic use*; D064232:Visual Analog Scale; D055815:Young Adult
D001559:Benzhydryl Compounds; D003408:Cresols; D064804:Urological Agents; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C041226:Terazosin; D011224:Prazosin